Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin glargine in adults with type 2 diabetes on basal-bolus therapy
NL-OMON54981Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Once-weekly insulin icodec + insulin aspart with Once-daily insulin glargine + insulin aspart (2 arms). Primary endpoint: Change in HbA1c from baseline to week 26. Started Jun 2021; status: active, not recruiting.
02
Drugs
insulin icodecinsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON54981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54981.